(Q46502474)

English

Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection

scientific article published on 4 July 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

0 references

1 reference

based on heuristic

inferred from title

author name string

Nobukazu Yuki

1

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

Takayuki Nagaoka

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

Kazuhiko Nukui

3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

Masao Omura

4

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

Kazumasa Hikiji

5

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

Michio Kato

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

publication date

4 July 2008

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

Journal of Gastroenterology

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

43

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

457-463

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

1 reference

https://api.crossref.org/works/10.1007%2FS00535-008-2174-9

21 January 2018

Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha 2a for chronic hepatitis B with e antigen or antibody:comparable antiviral effects on wild-type virus and precore mutant

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic hepatitis B with the sequential administration of interferon and lamivudine

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of HBV DNA sequences that are predictive of response to lamivudine therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns

1 reference

https://pubmed.ncbi.nlm.nih.gov/18600390

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-008-2174-9

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

release_oelkujnopvemvn4mrn7buzzqui

1 reference

https://api.fatcat.wiki/v0/release/oelkujnopvemvn4mrn7buzzqui

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/18600390

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46502474&oldid=2114510530"